Researchers have developed a simple model that characterizes the biomechanics of Ebola virus-host cell adhesion, findings that could provide new and helpful information on the road to developing an effective Ebola treatment.
In a breakthrough with applicability across many flu strains, researchers find a potential small molecule that mimics antibodies to treat disease.
The development and ultimate approval of tecovirimat for the antiviral treatment of smallpox, a disease that has been eradicated from the world for nearly 40 years, required a unique regulatory approach based on the US Food and Drug Administration's Animal Rule.
A pharmaceutical company has developed a conventional drug that mimics the effect of antibodies that are effective against a wide range of flu viruses. Conventional drugs are cheaper and easier to make and store than antibodies and can be taken in pill form. The hope is that this antibody-mimicking strategy could lead to new treatments for many viral diseases.
This paper summarizes clinical syndromes and possible treatment options, for both developed and low-resource settings, and offer performance indicators and clinical metrics for case management.
A detailed analysis of blood samples from Ebola patients in Sierra Leone is providing clues about the progression of the effects of the Ebola virus in patients and potential treatment pathways. The findings point to a critical role for a molecular pathway that relies on the common nutrient choline, as well as the importance of cellular bodies known as microvesicles.
Researchers amalgamated the expertise of two European Union expert networks: EMERGE (Efficient response to highly dangerous and emerging pathogens at EU level) and EVD-LabNet (Emerging Viral Diseases Laboratory Network), in order to select and analyze the relevant and some of controversial aspects of Crimean-Congo hemorrhagic fever (CCHF) disease diagnostics with implications for laboratory management of human CCHF cases and any exposed contacts.
Researchers showed that sofosbuvir, clinically approved against hepatitis C, inhibits yellow fever virus replication in liver cell lines and animal models. In vitro, sofosbuvir inhibits viral RNA replication, decreases the number of infected cells and the production of infectious virus particles.
These clinical practice guidelines are an update of the guidelines published by the Infectious Diseases Society of America (IDSA) in 2009, prior to the 2009 H1N1 influenza pandemic. This document addresses new information regarding diagnostic testing, treatment and chemoprophylaxis with antiviral medications, and issues related to institutional outbreak management for seasonal influenza.
Ebola could be transformed from a terrifying disease into something that can be managed at home if drug trials in the Democratic Republic of the Congo are successful, a leading scientist believes.